BioVie Inc. – NASDAQ:BIVI

BioVie stock price today

$1.59
-0.53
-25.35%
Financial Health
0
1
2
3
4
5
6
7
8
9

BioVie stock price monthly change

+359.25%
month

BioVie stock price quarterly change

+359.25%
quarter

BioVie stock price yearly change

+67.72%
year

BioVie key metrics

Market Cap
34.73M
Enterprise value
197.47M
P/E
-5.1
EV/Sales
N/A
EV/EBITDA
-5.33
Price/Sales
N/A
Price/Book
9.32
PEG ratio
-0.05
EPS
-1.1
Revenue
N/A
EBITDA
-41.10M
Income
-38.37M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

BioVie stock price history

BioVie stock forecast

BioVie financial statements

BioVie Inc. (NASDAQ:BIVI): Profit margin
Jun 2022 0 -5.97M
Mar 2023 0 -15.22M
Jun 2023 0 -9.11M
Mar 2024 0 -8.06M
BioVie Inc. (NASDAQ:BIVI): Analyst Estimates
2026 12.8M -43.82M -342.36%
2027 367.50M 140.65M 38.27%
  • Analysts Price target

  • Financials & Ratios estimates

BioVie Inc. (NASDAQ:BIVI): Earnings per share (EPS)
2022-11-04 -0.50665 -0.38
2023-02-10 -0.9901 -0.5
0%
Yield TTM
BioVie Inc. (NASDAQ:BIVI): Payout ratio
Payout ratio 0%
BioVie Inc. (NASDAQ:BIVI): Dividend Yield
2020 24.82%
2021
2022
2023
2024
BioVie Inc. (NASDAQ:BIVI): Debt to assets
Dec 2022 47191968 21.12M 44.76%
Mar 2023 45182696 23.46M 51.93%
Jun 2023 35104730 19.76M 56.3%
Mar 2024 31772861 12.84M 40.43%
BioVie Inc. (NASDAQ:BIVI): Cash Flow
Jun 2022 -5.86M 0 0
Mar 2023 -11.73M -12.50M 9.76M
Jun 2023 -11.28M -1.79M 1.26M
Mar 2024 -5.85M 0 15.97M

BioVie alternative data

BioVie Inc. (NASDAQ:BIVI): Employee count
Aug 2023 13
Sep 2023 18
Oct 2023 18
Nov 2023 18
Dec 2023 18
Jan 2024 18
Feb 2024 18
Mar 2024 18
Apr 2024 18
May 2024 18
Jun 2024 18
Jul 2024 18

BioVie other data

1.58% -2.91%
of BIVI is owned by hedge funds
491.50K -730.69K
shares is hold by hedge funds

BioVie Inc. (NASDAQ:BIVI): Insider trades (number of shares)
Period Buy Sel
May 2023 0 5000
Jun 2023 0 5984
Aug 2023 0 10805
Sep 2023 0 8560
Nov 2023 10000 0
Dec 2023 0 75680
Mar 2024 15000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
DO CUONG V director, officer: President & ..
Common stock 10,000 $1 $10,000
Purchase
DO CUONG V director, officer: President & ..
Warrants (right to buy) 5,000 $1.5 $7,500
Sale
GORLIN STEVE director
Common Stock 75,680 $1.69 $127,899
Purchase
DO CUONG V director, officer: President & ..
Common stock 10,000 $1.78 $17,800
Sale
GORLIN STEVE director
Common Stock 8,560 $3.05 $26,108
Sale
BERMAN RICHARD J director
Common Stock 10,805 $3.5 $37,828
Option
DO CUONG V director, officer: CEO & Presid..
Common Stock 41,506 N/A N/A
Option
DO CUONG V director, officer: CEO & Presid..
Restricted stock units 41,506 N/A N/A
Sale
BERMAN RICHARD J director
Common Stock 5,984 $5.81 $34,785
Sale
BERMAN RICHARD J director
Common Stock 5,000 $6.5 $32,505
Patent
Application
Filling date: 22 May 2020 Issue date: 28 Jul 2022
Application
Filling date: 18 Mar 2022 Issue date: 30 Jun 2022
Application
Filling date: 9 Apr 2019 Issue date: 5 Dec 2019
Insider Compensation
Mr. Jonathan M. Adams M.B.A., MBA (1963) Executive Vice President of Liver Disease Program
$267,200
Ms. Joanne Wendy Kim CPA (1955) Chief Financial Officer & Corporation Sec.
$120,620
Tuesday, 24 December 2024
accesswire.com
Sunday, 22 December 2024
accesswire.com
Wednesday, 18 December 2024
accesswire.com
Sunday, 15 December 2024
accesswire.com
Wednesday, 11 December 2024
accesswire.com
Monday, 28 October 2024
globenewswire.com
globenewswire.com
Thursday, 24 October 2024
globenewswire.com
Wednesday, 23 October 2024
globenewswire.com
Tuesday, 22 October 2024
globenewswire.com
Monday, 21 October 2024
globenewswire.com
Tuesday, 15 October 2024
globenewswire.com
Friday, 11 October 2024
accesswire.com
Wednesday, 25 September 2024
globenewswire.com
Tuesday, 24 September 2024
benzinga.com
Monday, 23 September 2024
globenewswire.com
globenewswire.com
Monday, 16 September 2024
globenewswire.com
Tuesday, 3 September 2024
globenewswire.com
Tuesday, 27 August 2024
globenewswire.com
Thursday, 8 August 2024
globenewswire.com
Tuesday, 6 August 2024
globenewswire.com
Friday, 5 July 2024
accesswire.com
Friday, 21 June 2024
accesswire.com
Thursday, 20 June 2024
globenewswire.com
Wednesday, 22 May 2024
globenewswire.com
Monday, 29 April 2024
Proactive Investors
Thursday, 25 April 2024
Proactive Investors
Tuesday, 12 March 2024
Zacks Investment Research
Monday, 11 March 2024
Proactive Investors
  • What's the price of BioVie stock today?

    One share of BioVie stock can currently be purchased for approximately $1.59.

  • When is BioVie's next earnings date?

    Unfortunately, BioVie's (BIVI) next earnings date is currently unknown.

  • Does BioVie pay dividends?

    No, BioVie does not pay dividends.

  • How much money does BioVie make?

    BioVie has a market capitalization of 34.73M. BioVie made a loss 32.12M US dollars in net income (profit) last year or -$0.5 on an earnings per share basis.

  • What is BioVie's stock symbol?

    BioVie Inc. is traded on the NASDAQ under the ticker symbol "BIVI".

  • What is BioVie's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of BioVie?

    Shares of BioVie can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are BioVie's key executives?

    BioVie's management team includes the following people:

    • Mr. Jonathan M. Adams M.B.A., MBA Executive Vice President of Liver Disease Program(age: 62, pay: $267,200)
    • Ms. Joanne Wendy Kim CPA Chief Financial Officer & Corporation Sec.(age: 70, pay: $120,620)
  • How many employees does BioVie have?

    As Jul 2024, BioVie employs 18 workers.

  • When BioVie went public?

    BioVie Inc. is publicly traded company for more then 4 years since IPO on 18 Sep 2020.

  • What is BioVie's official website?

    The official website for BioVie is bioviepharma.com.

  • Where are BioVie's headquarters?

    BioVie is headquartered at 680 West Nye Lane, Carson City, NV.

  • How can i contact BioVie?

    BioVie's mailing address is 680 West Nye Lane, Carson City, NV and company can be reached via phone at +7 758883162.

BioVie company profile:

BioVie Inc.

bioviepharma.com
Exchange:

NASDAQ

Full time employees:

14

Industry:

Biotechnology

Sector:

Healthcare

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

680 West Nye Lane
Carson City, NV 89703

CIK: 0001580149
ISIN: US09074F2074
CUSIP: 09074F207